Welcome To Website IAS

Hot news
Achievement

Independence Award

- First Rank - Second Rank - Third Rank

Labour Award

- First Rank - Second Rank -Third Rank

National Award

 - Study on food stuff for animal(2005)

 - Study on rice breeding for export and domestic consumption(2005)

VIFOTEC Award

- Hybrid Maize by Single Cross V2002 (2003)

- Tomato Grafting to Manage Ralstonia Disease(2005)

- Cassava variety KM140(2010)

Centres
Website links
Vietnamese calendar
Library
Visitors summary
 Curently online :  6
 Total visitors :  4511072

First Human Trial of COVID-19 Vaccine Found Safe and Induces Rapid Immune Response
Monday, 2020/06/01 | 08:24:51

ISAAA News - May 27, 2020

 

New research published in The Lancet reports that the first COVID-19 vaccine to reach phase 1 clinical trial has been found to be safe, well-tolerated, and able to generate an immune response against SARS-CoV-2 in humans. The open-label trial in 108 healthy adults showed promising results after 28 days, while the final results will be evaluated in six months. Further trials are needed to tell whether the immune response that the vaccine elicits effectively protects against SARS-CoV-2 infection.

 

Between March 16 and March 27, 2020, 195 individuals were screened for their eligibility for the trials of an Ad5 vectored COVID-19 vaccine candidate in a rehabilitation center in Wuhan, Hubei province, China. Of these individuals, 108 participants (51% male, 49% female; mean age 36.3 years) were recruited and received the low dose (n=36), middle dose (n=36), or high dose (n=36) of the vaccine. Participants reported mild or moderate adverse reactions such as fever (50 [46%]), fatigue (47 [44%]), headache (42 [39%]), and muscle pain (18 [17%]). However, the research group pointed out that the severe adverse reactions were transient and self-limiting. Antibodies and neutralizing antibodies increased significantly at day 14, and peaked 28 days post-vaccination.

 

"These results represent an important milestone. The trial demonstrates that a single dose of the new adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine produces virus-specific antibodies and T cells in 14 days, making it a potential candidate for further investigation," says Professor Wei Chen from the Beijing Institute of Biotechnology in Beijing, China, who is responsible for the study.

 

For more details, read the online-first article in The Lancet.

 

Figure 2:  Flow cytometry with intracellular cytokine staining before and after vaccination

Back      Print      View: 22

[ Other News ]___________________________________________________
  • Beyond genes: Protein atlas scores nitrogen fixing duet
  • 2016 Borlaug CAST Communication Award Goes to Dr. Kevin Folta
  • FAO and NEPAD team up to boost rural youth employment in Benin, Cameroon, Malawi and Niger
  • Timely seed distributions in Ethiopia boost crop yields, strengthen communities’ resilience
  • Parliaments must work together in the final stretch against hunger
  • Empowering women farmers in the polder communities of Bangladesh
  • Depression: let’s talk
  • As APEC Concludes, CIP’s Food Security and Climate Smart Agriculture on Full Display
  • CIAT directly engages with the European Cocoa Industry
  • Breeding tool plays a key role in program planning
  • FAO: Transform Agriculture to Address Global Challenges
  • Uganda Holds Banana Research Training for African Scientists and Biotechnology Regulators
  • US Congress Ratifies Historic Global Food Security Treaty
  • Fruit Fly`s Genetic Code Revealed
  • Seminar at EU Parliament Tackles GM Crops Concerns
  • JICA and IRRI ignites a “seed revolution” for African and Asian farmers
  • OsABCG26 Vital in Anther Cuticle and Pollen Exine Formation in Rice
  • Akira Tanaka, IRRI’s first physiologist, passes away
  • WHO calls for immediate safe evacuation of the sick and wounded from conflict areas
  • Farmer Field School in Tonga continues to break new ground in the Pacific for training young farmers
Designed & Powered by WEBSO CO.,LTD